Recently, it has been demonstrated that in vivo MEKi, when used in combination with PD-L1 checkpoint blockade, potentiate T-cell-mediated anti-tumor immunity by increasing the frequency of intratumoral antigen-specific effector CD8+ T cells [17]. This evidence concerns the gene CD274 and neoplasm.